Skip to main content
TipRanks
Go Ultimate75% OFF

Maravai Lifesciences Holdings (MRVI) Adjusted EBITDA by Segment

426 Followers

Adjusted EBITDA by Segment

Maravai Lifesciences Holdings reported adjusted EBITDA by segment of $14.92M in Q3 2026, down 18.9% from Q2 2026 and up 468.2% year over year. The highest value was $200.39M in Q2 2022.

Shows profitability across different business units, highlighting which segments are driving earnings and where there might be opportunities or challenges in cost management.

-$50.00M$0.00$50.00M$100.00M$150.00M$200.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Nucleic Acid Production has been the swing factor—driving big EBITDA peaks early, collapsing during the post‑COVID/convert-to‑GMP reset, and only recently returning to positive contribution as TriLink shifts to higher‑margin GMP and discovery mix. Biologics Safety Testing (Cygnus) is the steady, high‑margin backbone delivering consistent EBITDA. Management’s guidance and margin commentary signal genuine profit momentum, but sustaining it hinges on converting lumpy GMP/CDMO orders and new GMP product commercialization timing despite a stronger balance sheet.

MRVI Adjusted EBITDA by Segment

PeriodNucleic Acid ProductionBiologics Safety TestingTotal
Q3 2026Sep 30, 2026$2.46M$12.46M$14.92M
Q2 2026Jun 30, 2026$7.03M$11.38M$18.40M
Q1 2026Mar 31, 2026$17.26M$13.56M$30.82M
Q4 2025Dec 31, 2025$936.00K$10.17M$11.10M
Q3 2025Sep 30, 2025-$7.92M$10.54M$2.63M
Q2 2025Jun 30, 2025-$7.27M$10.86M$3.59M
Q1 2025Mar 31, 2025-$8.90M$12.67M$3.77M
Q4 2024Dec 31, 2024$3.97M$9.54M$13.51M
Q3 2024Sep 30, 2024$15.46M$10.93M$26.38M
Q2 2024Jun 30, 2024$21.30M$9.45M$30.75M
Q1 2024Mar 31, 2024$10.09M$13.93M$24.01M
Q4 2023Dec 31, 2023$24.00M$11.60M$35.60M
Q3 2023Sep 30, 2023$16.59M$11.25M$27.84M
Q2 2023Jun 30, 2023$14.19M$10.31M$24.51M
Q1 2023Mar 31, 2023$27.87M$13.75M$41.62M
Q4 2022Dec 31, 2022$135.43M$11.21M$146.64M
Q3 2022Sep 30, 2022$133.82M$13.00M$146.81M
Q2 2022Jun 30, 2022$186.29M$14.10M$200.39M
Q1 2022Mar 31, 2022$182.80M$16.53M$199.33M
Q4 2021Dec 31, 2021$163.56M$12.26M$175.81M
Q3 2021Sep 30, 2021$150.35M$13.60M$163.95M
Q2 2021Jun 30, 2021$156.32M$14.29M$170.61M
Q1 2021Mar 31, 2021$95.03M$14.29M$109.32M
Q4 2020Dec 31, 2020$57.69M$10.95M$68.64M
Q3 2020Sep 30, 2020$46.70M$12.00M$58.70M
Q2 2020Jun 30, 2020$10.60M$9.63M$20.23M
Q1 2020Mar 31, 2020$18.83M$11.94M$30.77M

Related KPIs